Skip to Main Content

The International Low Grade Glioma Registry

Dr. Elizabeth Claus
Professor at the Yale School of Public Health and a principal investigator for the Low-grade Glioma Registry and Optimum Study speaks frequently with patients and physicians about low-grade glioma.

One of the most critical questions in the field of neuro-oncology today is how to best manage and treat low-grade glioma (LGG), a malignant tumor of the brain. Dr. Elizabeth B. Claus, Professor and Director of Medical Research, Yale School of Public Health and attending neurosurgeon and Director of Stereotactic Radiosurgery, Department of Neurosurgery, Brigham and Women’s Hospital has focused her research and clinical practice on this malignant tumor. To reduce this knowledge gap, the International Low-Grade Glioma Registry has been launched. The purpose of this registry is to discover why some people develop LGG while other people do not. The goal is also to learn more about the effect of this diagnosis and the associated treatments on daily life including the ability to work, drive, sleep, exercise, or take care of oneself and/or family.

Who can enter the study?

Any person currently 21 years of age or older (regardless of age at LGG diagnosis) with an initial diagnosis of grade II/III glioma (i.e. oligodendroglioma, astrocytoma).

The study asks participants to:
  1. Provide a pathology report,
  2. Complete an online questionnaire and
  3. Provide a saliva sample that will permit us to look at changes in DNA.
If you allow, we will also review your tissue specimens and MRI scans of your LGG. Some participants will be asked to contribute activity data and perform neurocognitive tasks via their smartphone.